Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B

• US 7,468,391 B2
• Filed: 12/13/2004
• Issued: 12/23/2008
• Est. Priority Date: 12/17/2003
• Status: Expired due to Fees

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Wang, Liming, Li, Ling, Vu, Thong, Bhat, Smita, Takeuchi, Janet, Chandraratna, Roshantha A., Beard, Richard, Tsang, Kwok-Yin, Vasudevan, Jayasree, Yang, Rong, Liu, Xiaoxia
• Primary Examiner(s): Hartley; Michael G.
• Assistant Examiner(s): Westerberg; Nissa M
• Application Number:
  US11/010,953
• Publication Number:
  US 20050187298A1
• Time in Patent Office: 1,471 Days
• Field of Search: None
• US Class Current: 514/567
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 31/38 having sulfur as a ring hetero atom
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

Claims

1. A method for treating an individual having a retinoid responsive skin disorder selected from the group consisting of acne, psoriasis, eczema, atopic dermatitis, Pityriasis rubra pilaris, multiple basal cell carcinomasactinic keratoses, arsenic keratoses, ichthyoses, Darriers disease, lichen planus, glucocorticoid damage, microbial infection of the skin, excessive pigmentation of the skin, and photodamage of the skin, comprising administering to said individual an effective amount of a selective CYP26A inhibitor having a formula selected from:

2. The method of claim 1, wherein said administering is oral administering.

3. The method of claim 1, wherein said inhibitor is administered peripherally.

4. The method of claim 1, wherein said individual is a human.

5. The method of claim 1, wherein the retinoid responsive skin disorder is acne, psoriasis or eczema.

6. A method for treating an individual having a retinoid responsive skin disorder selected from the group consisting of acne, psoriasis, eczema, atopic dermatitis, Pityriasis rubra pilaris, multiple basal cell carcinomasactinic keratoses, arsenic keratoses, ichthyoses, Darriers disease, lichen planus, glucocorticoid damage, microbial infection of the skin, excessive pigmentation of the skin, and photodamage of the skin, comprising administering to said individual an effective amount of a selective CYP26A selected from:

7. A method for treating an individual having acne, comprising administering to said individual an effective amount of a selective CYP26A inhibitor having a formula selected from:

8. The method of claim 7, wherein said administering is oral administering.

9. The method of claim 7, wherein said inhibitor is administered peripherally.

10. The method of claim 7, wherein said individual is a human.

11. The method of claim 7, wherein the acne is selected from the group consisting of superficial acne, deep acne, acne vulgaris, acne conglobata, acne fulminans, acne medicamentosa, comedonal acne and cystic acne.

12. A method for treating an individual having acne, comprising administering to said individual an effective amount of a selective CYP26A inhibitor selected from: